OncoMatch/Clinical Trials/NCT07028853
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Is NCT07028853 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Mevrometostat and Enzalutamide for metastatic castration sensitive prostate cancer (mcspc).
Treatment: Mevrometostat · Enzalutamide — This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Exception: first-generation antiandrogen (ADT) agents allowed for mCSPC
Participants must be treatment naïve at the mCSPC stage, eg, participants cannot have received any cytotoxic chemotherapy with the following exceptions: Treatment with first-generation antiandrogen (ADT) agents is allowed for mCSPC.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clearview Cancer Institute (Crestwood) · Huntsville, Alabama
- Clearview Cancer Institute · Huntsville, Alabama
- Ironwood Cancer & Research Centers · Chandler, Arizona
- Ironwood Cancer & Research Centers · Gilbert, Arizona
- Ironwood Cancer & Research Centers · Glendale, Arizona
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify